<![CDATA[Biomarker-Independent ADC Rina-S Advances to Phase 3 in Endometrial Cancer]]>

Phase 3rinatabart sesutecanPositive

AI Analysis

Summary

Rinatabart sesutecan, an FRα-directed antibody-drug conjugate, advances to the Phase 3 RAINFOL-03 trial for endometrial cancer after demonstrating disease control independent of biomarker status.

Clinical Trial Data

Phase

Outcome Details

FRα-directed ADC showed disease control regardless of biomarker status

Importance:7/10

Sentiment:

0.60

ADCendometrial cancerbiomarker-independentFRα-directedphase 3 advancement

Read the original article

Published by Cancer Network on August 26, 2026 8:00 PM

Read Original